Syngene International Limited, an integrated research, development and manufacturing organisation, announced the appointment of Dr Carl Decicco as Additional Director of the company, effective March 1, 2022.
According to the company’s exchange filing, “It is further informed that the Board of Directors has approved the appointment of Dr Carl Decicco as Additional Director (Non-executive Non-independent) of the Company with effect from March 01, 2022 till three months from the date of his appointment or the next general meeting of the Company, whichever is earlier.”
Dr Carl Decicco completed post-doctoral studies with Professor EJ Corey at Harvard University. He was a teaching fellow at the University of British Columbia and obtained his Ph.D. with Professor Gordon Lange in Organic Chemistry from the Guelph-Waterloo Center in Ontario, Canada.
He has 22 years of experience in the pharmaceutical industry. Dr. Decicco retired as the Chief Scientific Officer at Foghorn Therapeutics in Cambridge MA in January 2022. Prior to joining Foghorn in 2018, he served as the Head of Discovery at Bristol Myers Squibb (BMS). He is a Partner at Flagship Pioneering and serves on the Board of Cellarity Pharmaceuticals.
